GlaxoSmithKline

IDRx is a clinical-stage biopharmaceutical company focused on developing precision therapies for oncology, specifically targeting gastrointestinal stromal tumors. The company specializes in designing precision combination therapies that utilize engineered drug combinations to address key tumor escape mechanisms and enhance the duration of therapeutic responses. Through its innovative approach, IDRx aims to transform cancer treatment by enabling healthcare professionals to create targeted cancer medicines tailored to individual patient needs.

Asceneuron SA, established in 2012 and headquartered in Lausanne, Switzerland, is a biotechnology subsidiary of Merck KGaA dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. The company focuses on progressive supranuclear palsy, orphan tauopathies, Alzheimer's disease, and Parkinson's disease, aiming to provide effective treatments where none currently exist or are limited in their benefits. Asceneuron operates by targeting the underlying causes of these debilitating conditions, such as abnormal tau protein deposits, with the goal of developing orally bioavailable therapeutics that can improve patients' lives and address the growing healthcare burden posed by neurodegenerative diseases.

Aiolos Bio is a biotechnology company specializing in the development of therapies for respiratory diseases and immune conditions. Its primary focus is on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma, designed for dosing every 6 months. The company, founded by industry veterans, aims to address unmet treatment needs and improve patient outcomes by providing more efficacious and less burdensome therapies.

Canadian Centre for Vaccinology is an integrated collaborative interdisciplinary vaccine research team committed to excellent research.

Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

WaVe Life Sciences Ltd. is a clinical-stage genetic medicine company based in Singapore, focused on developing innovative treatments for genetically defined diseases using its proprietary PRISM platform. This platform enables the precise design, optimization, and production of stereopure oligonucleotides, which are designed to target genetic defects by either reducing harmful protein expression or converting dysfunctional proteins into functional ones. The company's primary focus is on neurology, particularly within the central and neuromuscular systems. WaVe Life Sciences collaborates with major pharmaceutical companies, including Pfizer and Takeda, to advance the research and development of its oligonucleotide therapeutics. Founded in 2012, the company aims to deliver transformative therapies to improve patient outcomes in both rare and prevalent disorders.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing targeted therapies for hematology and oncology patients. Founded in 2003 and headquartered in Vancouver, Canada, the company focuses on delivering innovative treatments for rare forms of cancer. Its lead drug candidate, momelotinib, is a selective inhibitor of JAK1, JAK2, and ACVR1, which has been evaluated in two completed Phase 3 trials for myelofibrosis. In addition, Sierra is advancing SRA737, an inhibitor of Checkpoint kinase 1 currently undergoing Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase in preclinical development. Through its scientific expertise and evidence-based approach, Sierra Oncology aims to transform cancer treatment paradigms and improve patient outcomes.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Adrestia Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2017. The company specializes in developing therapeutics aimed at restoring the biological balance in damaged, diseased, and dying cells. Adrestia Therapeutics is recognized for its expertise in synthetic rescue, an innovative approach that decodes complex genetic networks to identify novel treatment strategies for various diseases. In addition to therapeutic development, the company provides basic and applied research, as well as experimental development services tailored to the biotechnology industry.

CureVac is a clinical-stage biopharmaceutical company based in Germany, established in 2000, that specializes in developing vaccines and therapies utilizing messenger ribonucleic acid (mRNA). The company focuses on both prophylactic and therapeutic applications of mRNA, enabling the human body to produce proteins that combat various diseases. CureVac's innovative pipeline includes mRNA-based cancer immunotherapies, such as CV9104, which is in Phase IIb development for prostate cancer, as well as RNActive vaccines against infectious diseases and RNArt molecular therapies designed to stimulate the production of therapeutic proteins. Additionally, the company has collaborated with GSK to advance second-generation vaccines for seasonal influenza and COVID-19, alongside an avian influenza vaccine, while also exploring mRNA therapies for oncology and other conditions affecting the liver and eyes.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.

Sitari Pharmaceuticals is a operator of a biotechnology company intended to develop treatments for multiple disease indications with an initial focus in celiac disease.

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company employs a precision medicine approach to create targeted oncology solutions. Its lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing mirdametinib, an oral small molecule MEK inhibitor, which is undergoing Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas. The company is also exploring various combination therapies involving nirogacestat and mirdametinib for multiple myeloma and solid tumors. SpringWorks has established collaborations with notable organizations to enhance its research and development efforts, aiming to unlock new treatment options for underserved patient populations.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Atreca, Inc. is a biopharmaceutical company focused on the discovery and development of antibody-based immunotherapeutics for various solid tumor types. Founded in 2010 and headquartered in South San Francisco, California, Atreca utilizes a unique platform to identify antibodies produced during immune responses, facilitating the development of novel therapies without prior knowledge of antigens. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, targeting a range of cancers including ovarian, non-small cell lung, colorectal, and breast cancer. The company has established a strategic research collaboration with Merck Sharp & Dohme Corp. to explore antigenic targets for select antibodies with potential applications in oncology.

Gladius Pharmaceuticals Inc. is a biotechnology firm based in Montréal that focuses on developing innovative antibiotics to address life-threatening, multi-drug-resistant bacterial infections. The company is dedicated to creating novel drug candidates that demonstrate broad-spectrum efficacy against gram-negative pathogens. Gladius's antibiotics aim to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby providing physicians with effective treatment options for challenging bacterial infections.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

GlycoVaxyn AG is a biopharmaceutical company based in Schlieren, Switzerland, specializing in the development and manufacture of biological conjugation vaccines targeting bacterial infections. Established in 2004, the company employs recombinant DNA technology to create immunogenic glycoprotein conjugate vaccines for various bacterial diseases, including pneumococcal and nosocomial infections. GlycoVaxyn's innovative approach allows for the conjugation of carbohydrates to proteins, resulting in well-characterized molecules that demonstrate high consistency and reproducibility across batches. This technology is instrumental in creating new prophylactic and therapeutic vaccines, contributing to the prevention and treatment of bacterial infections. As of February 2015, GlycoVaxyn operates as a subsidiary of GlaxoSmithKline plc.

Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that regulates the iron supply for red blood cell production. Iron deficiency, also known as anemia, is a condition in which blood does not contain the normal amount of red blood cells or lacks the proper amount of hemoglobin. This, in turn, lowers the amount of oxygen-rich blood in circulation, causing shortness of breath, dizziness or headaches.

Thyritope Biosciences is developing therapeutics that target thyroid stimulating auto-antibodies, which are the causative drivers of Graves' hyperthyroidism and Graves' orbitopathy. Graves' disease is an autoimmune disorder caused by antibodies that over-stimulate the thyroid, causing excessive thyroid hormone production. The same antibodies stimulate the tissue around the eyes, resulting in an increase of orbital fat and extra-ocular muscle volume which causes the bulging of the eyes characteristic of Graves' orbitopathy.

Sitari Pharmaceuticals is a operator of a biotechnology company intended to develop treatments for multiple disease indications with an initial focus in celiac disease.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.

Okairos AG is a biopharmaceutical company headquartered in Basel, Switzerland, with operations in Rome and Naples, Italy. The company specializes in the discovery and development of genetic T-cell vaccines, focusing on conditions such as hepatitis C virus. Okairos also excels in gene delivery technologies, providing expertise in scalable viral-vector manufacturing processes. This enables other biotech firms to transition genetic vaccines and medicinal products from preclinical stages to commercial readiness, utilizing advanced good manufacturing practice (GMP) facilities. Previously a subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Okairos is dedicated to advancing innovative therapeutic solutions in the healthcare sector.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Human Genome Sciences is a biopharmaceutical company that specializes in the development of innovative pharmaceutical products through genomic research. The company is focused on advancing its pipeline of therapies, with three products currently in late-stage clinical development. By leveraging genomic insights, Human Genome Sciences aims to address unmet medical needs and improve patient outcomes in various therapeutic areas.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

CellZome is a pharmaceutical company based in Heidelberg, Baden-Württemberg, founded in 2000. The company specializes in the discovery, development, and commercialization of kinase-targeted drugs aimed at treating inflammatory diseases. CellZome focuses on creating a pipeline of kinase inhibitors that target inflammatory mediators, developing oral therapeutics for conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drugs to treat autoimmune and central nervous system disorders. The company employs a unique precision deuterium chemistry platform to modify the properties of validated drug molecules, resulting in a diverse pipeline of new chemical entities. Key product candidates include CTP-543, which is in Phase III trials for alopecia areata, and CTP-692, undergoing Phase II trials for schizophrenia. Additionally, AVP-786, a combination therapy for neurologic and psychiatric disorders, is also in Phase III trials. Concert Pharmaceuticals aims to enhance drug safety and efficacy while minimizing research and development risks and costs. Established in 2006 and based in Lexington, Massachusetts, the company has formed strategic collaborations with several pharmaceutical partners to advance its innovative drug development efforts.

Maxinutrition Group is a leading producer of protein-enhanced functional nutrition products based in England. As the parent company of recognized brands such as Maximuscle, Maxifuel, and Maxitone, it specializes in catering to diverse consumer needs within the sports nutrition sector. Maximuscle targets individuals focused on muscle gain and strength enhancement, while Maxifuel was developed for athletes prioritizing endurance and performance. Additionally, the Maxitone range is designed specifically for health-conscious women, promoting toning and weight management. Beyond nutritional supplements, Maxinutrition also offers related training accessories to support various fitness endeavors, enabling customers to access a broad spectrum of products for their performance and wellness goals.

Semprus BioSciences is a biomedical company based in Cambridge, Massachusetts, specializing in innovative medical device technology. The company has developed a unique antimicrobial coating technology designed for vascular access catheters, which aims to reduce microbial adherence and thrombus accumulation throughout the device's lifespan. This breakthrough enables the coating of devices of various sizes, shapes, and materials, enhancing their performance and safety. Semprus has successfully secured funding, raising a total of $28.5 million through multiple financing rounds, including a significant Series B round co-led by notable venture capital firms.

Nanjing MeiRui Pharma Co., Ltd. operates as a pharmaceutical business with a strong portfolio of urology and allergy products, including Prostat for benign prostatic hyperplasia and Sheniting for overactive bladder syndrome.

Laboratorios Phoenix is an international pharmaceutical company headquartered in Argentina. It manufactures and distributes a wide array of pharmaceutical products within the country, focusing on branded generic medications. Their portfolio spans various therapeutic areas such as cardiovascular, gastroenterology, metabolic disorders, urology, antiseptics, over-the-counter drugs, dietary supplements, vitamins, and minerals.

NovaMin Technology provides a range of oral hygiene solutions. The company was founded by Randy Scott in 2004 and is based in Alachua, Florida.

NeuroTherapeutics Pharma, Inc., a biopharmaceutical company, develops therapeutics for patients suffering from central nervous system disorders. It focuses on epilepsy, neuropathic, and acute pain disorders of the nervous system. The company was incorporated in 2006 and is based in Chicago, Illinois.

Genmab is a biotechnology company based in Copenhagen that specializes in the development of fully human antibody therapeutics aimed at treating cancer and other serious diseases. The company employs advanced proprietary technologies, including DuoBody, HexaBody, DuoHexaBody, and HexElect, to create innovative therapies designed to meet unmet medical needs. Genmab's leading product, Darzalex, developed in partnership with Johnson & Johnson, is recognized as the standard treatment for multiple myeloma. In addition to Darzalex, the company's portfolio includes Tepezza for thyroid eye disease, Kesimpta for relapsing multiple sclerosis, Rybrevant for non-small cell lung cancer, Tivdak for cervical cancer, and Epkinly, all of which are developed in collaboration with various pharmaceutical partners. Through its commitment to research and development, Genmab aims to deliver transformative therapies that improve patient outcomes.

Chroma Therapeutics Ltd., established in 2000, is a privately-held biotechnology company based in Abingdon, UK. It specializes in developing novel small molecule drugs for targeted cancer and inflammation treatments, drawing from chromatin biology and innovative cell accumulation approaches. The company's pipeline includes Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for cancer treatment; and CHR-2845, a targeted solution for hematological malignancies. Chroma has built a strong network of academic collaborators and holds the first systematic assembly of intellectual property in chromatin biology, aiming to create substantial shareholder value through its innovative product pipeline targeting high-prevalence diseases.

Stiefel Laboratories, a subsidiary of GlaxoSmithKline, is a leading global company focused exclusively on dermatology and skin science. It operates more than 30 wholly-owned subsidiaries and six manufacturing plants across various countries, supported by a global research and development network. With a workforce of nearly 3,500 associates, Stiefel is dedicated to delivering innovative ethical, over-the-counter, and aesthetic dermatological products to customers in over 100 countries. Notable brands under its portfolio include Sarna, Duac Topical Gel, Olux, and Brevoxyl. The company invests over $100 million annually in developing advanced skin health solutions, reflecting its commitment to improving current treatments and exploring future innovations in dermatology.

Genelabs Technologies Inc. is a biopharmaceutical company based in Redwood City, California, focused on the discovery and development of therapies for infectious diseases. Founded in 1983, the company aims to improve human health through targeted research on high-value projects. Its product pipeline includes initiatives for treating Hepatitis C, as well as late-stage clinical assets like an investigational vaccine for hepatitis E and Prestara, a drug for systemic lupus erythematosus. Genelabs has established collaborative agreements with notable organizations, including the Novartis Institutes for BioMedical Research and Genovate Biotechnology Co., Ltd., to advance its research efforts in combating Hepatitis C. In 2009, Genelabs Technologies was acquired by SmithKline Beecham Corporation, further integrating its capabilities within a larger pharmaceutical framework.

BMS - Egyptian Mature Products Business provides pharmaceutical products.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Reliant Pharmaceuticals is a company focused on developing and marketing cardiovascular pharmaceutical products. Established in 1999 and headquartered in Liberty Corner, New Jersey, it offers a range of medications designed to treat conditions such as hypertension, elevated cholesterol, and acid reflux disease. Its product portfolio includes Axid for acid reflux, InnoPran XL and DynaCirc CR for hypertension, Omacor for high triglycerides, and Rythmol SR. The company is involved in acquiring and developing branded pharmaceuticals, as well as potential products that are in mid- to late-stage clinical development. Reliant Pharmaceuticals distributes its products primarily to physicians in primary care, cardiovascular, and specialized medical fields.

Praecis Pharmaceuticals, Inc. operates as a biopharmaceutical company, engages in the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.

Domantis Ltd. develops antibody molecules. Domantis Ltd. offers dual targeting human domain antibodies, which are used against cytokine targets for inflammatory diseases, tumour antigens present on the same tumour cells, and tumour growth/angiogenic factors for solid tumours; human domain antibodies with tailored serum half-life that are customized to achieve the desired therapeutic effect; human domain antibodies for diverse therapeutic targets, which are suited to inhibit receptor targets; and injectable and non-injectable human domain antibodies that treat diseases of the lung, as well as disorders of the gastro-intestinal tract.

CNS, Inc. was acquired by GlaxoSmithKline Consumer Healthcare, L.P. CNS, Inc. engages in the development and marketing of consumer health care products for better breathing and digestive health markets. The company’s primary products include Breathe Right nasal strips, a nonprescription single-use disposable device that improves breathing by opening the nasal passages; Breathe Right Snore Relief throat spray, a drug-free product that addresses the snoring condition; Breathe Right Vapor Shot! personal vaporizer; Breathe Right saline nasal spray; and FiberChoice, an orange-flavored chewable fiber tablet that supplements the consumer’s daily intake of dietary fiber. CNS markets its products through direct sales force and national brokerage organizations to mass merchandise stores, drug stores, grocery stores, warehouse clubs, military base stores, and online retailers in the United States, as well as through distributors, sales representatives, and suppliers internationally. The company was founded in 1982 and is headquartered in Minneapolis, Minnesota. Source : (Businessweek) {http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=171706}

ID Biomedical Corporation develops and markets vaccine products. The company markets Fluviral, an injectable vaccine for influenza, as well as NeisVac-C for Meningococcal Group C disease in Canada. It also distributes NeisVac-C under license from Baxter Corporation.

Corixa was a developer of immunotherapeutics founded in 1994, dedicated to treating and preventing autoimmune diseases, cancer, and infectious diseases by understanding and directing the immune system. The company engaged in various preclinical development programs, including BEXXAR® therapy and MELACINE® vaccine. Corixa focused on immunotherapeutic products, possessing a broad technology platform that facilitated integrated vaccine design and the use of proprietary product components independently. The company established partnerships with numerous pharmaceutical developers and marketers to enhance the availability of its products. In July 2005, Corixa was acquired by GlaxoSmithKline, which utilized Corixa's MPL adjuvant in some of its vaccines. However, Corixa ultimately ceased operations in March 2006.

Europharm Holding SA distributes pharmaceutical products. Europharm Holding operates as a subsidiary of GlaxoSmithKline.

Block Drug Co., Inc. manufactures denture care products, oral health care products, consumer over-the-counter medications, and professional dental products.